To account for the genetic-drivers that may underlie responses to ICI and to be able to use C57BL6 syngeneic tumor model, we used B6/lpr mice and a continuous administration of anti-PD-1 and anti-CTLA-4 antibodies (Fig 1A). The gene discussed is CTLA4; the disease is neoplasm.